Insider Selling: Regeneron Pharmaceuticals (NASDAQ:REGN) Director Sells $320,000.00 in Stock

Posted by Francis Steltz on Aug 12th, 2026

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) Director Kathryn Guarini sold 400 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $800.00, for a total value of $320,000.00. Following the completion of the sale, the director directly owned 603 shares in the company, valued at $482,400. This trade represents a 39.88% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock traded up $0.99 during trading hours on Wednesday, reaching $797.99. 571,786 shares of the company’s stock were exchanged, compared to its average volume of 859,210. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $541.00 and a fifty-two week high of $821.11. The stock has a market capitalization of $82.16 billion, a P/E ratio of 19.72, a P/E/G ratio of 1.37 and a beta of 0.22. The business has a fifty day moving average price of $665.31 and a 200-day moving average price of $713.04. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.16 by $4.13. The business had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. Regeneron Pharmaceuticals’s revenue was up 16.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $12.81 earnings per share. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th will be issued a dividend of $0.94 per share. The ex-dividend date is Tuesday, August 18th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is presently 9.29%.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in REGN. Quantbot Technologies LP acquired a new stake in Regeneron Pharmaceuticals during the second quarter valued at approximately $910,000. Evolve Private Wealth LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter worth approximately $785,000. Varma Mutual Pension Insurance Co bought a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth approximately $11,528,000. Westpac Banking Corp acquired a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at $4,402,000. Finally, TRB Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at $206,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on REGN. Canaccord Genuity Group decreased their target price on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating on the stock in a research report on Tuesday, May 19th. Piper Sandler cut their price target on Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating for the company in a report on Thursday, July 9th. Morgan Stanley lifted their price objective on Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the stock an “equal weight” rating in a report on Friday, July 31st. Barclays lowered their price objective on Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating on the stock in a research report on Thursday, April 30th. Finally, Citigroup upped their target price on Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the company a “neutral” rating in a research note on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and ten have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $797.75.

Get Our Latest Stock Analysis on Regeneron Pharmaceuticals

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

Positive Sentiment: Regeneron’s Eylea HD and Dupixent franchises continue to support growth, while oncology products and pipeline progress provide additional catalysts. The company’s shares were described as having risen 21.9% over the past month. REGN Soars 21.9% in a Month: Buy, Sell or Hold the Stock?
Positive Sentiment: Goldman Sachs maintained its Buy rating on Regeneron, signaling continued confidence in the company’s outlook despite recent clinical and legal concerns. Goldman Sachs Keeps Their Buy Rating on Regeneron
Neutral Sentiment: Multiple law firms repeated notices that investors have until September 14, 2026 to seek lead-plaintiff status in a securities class action. The announcements largely repeat the same lawsuit rather than disclose a new company development. Regeneron Class Action Lawsuit Notice
Negative Sentiment: The litigation stems from allegations that Regeneron misled investors about the viability of its Phase 3 Fianlimab-Libtayo trial for advanced melanoma. The trial’s failure reportedly erased approximately $11 billion in market value, increasing legal and reputational risk. REGN Stockholders Class Action Notice

Regeneron Pharmaceuticals Company Profile

(Get Free Report)

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.